ProPhase Labs, Inc.

PRPH Healthcare Diagnostics & Research

In the quarter to June 2026, revenue fell 18.9%, EPS grew 80.0%, free cash flow grew 56.7% and total debt rose 19.4%, each against the same quarter a year earlier.

0.01 0.00 0.00%
Market cap
$1.2M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
4/9
Altman Z
−3.59
Beneish M
−4.90
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.85 0.00 0.00 0.00 17.93 7.98 0.00 0.00 0.00
Piotroski F-Score
4 6 4 4 3 6 7 1 1 4
P/S ratio
8.24 3.53 2.73 2.31 7.33 1.38 1.24 2.28 2.25 0.88
Altman Z-Score
0.46 12.90 6.58 13.75 3.51 4.03 6.90 0.99 (3.07) (3.59)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 6.05 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(4.66) 24.87 8.71 13.95 1.71 6.21 8.38 1.40 (7.14) (11.41)
P/Operating CF
87.12 (20.20) (45.96) (53.23) (15.73) (23.41) 186.97 (106.03) (4.32) (3.11)
Beneish M-Score
(3.21) (1.32) (3.31) (3.06) (4.60) 3.42 (2.87) (1.35) — (4.90)
P/B ratio
5.82 1.09 2.18 2.03 10.08 1.86 2.38 1.62 2.07 1.09
Price to Tangible BV
14.54 1.23 2.78 2.98 12.64 2.59 3.07 2.51 0.00 0.00
EV/Sales
8.84 1.61 2.33 2.47 7.46 1.29 1.12 2.55 4.72 2.19
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 7.63 4.78 0.00 0.00 0.00
EV/Operating CF
(78.80) (5.60) (14.45) (28.99) (41.79) (7.49) 4.80 (7.51) (1.82) (1.14)
EV/FCF
(33.12) (5.22) (0.71) (22.81) (49.23) (3.79) 5.46 (6.41) (1.76) (1.16)
Quick Ratio
0.91 14.56 3.79 8.77 1.84 3.56 3.39 1.94 0.65 0.03
Current Ratio
1.41 15.68 4.31 10.66 2.52 3.95 3.78 2.28 0.95 0.06
Net Debt/EBITDA
(0.31) 6.02 6.59 0.48 (1.15) (0.51) (0.51) (0.46) (0.55) (0.74)
Debt/Assets
11.64% 0.00% 0.00% 0.00% 32.86% 11.99% 3.08% 12.43% 27.61% 9.68%
Debt/Equity
0.25 0.00 0.00 0.00 0.98 0.18 0.04 0.23 2.37 1.65
Asset Turnover
0.30 0.42 0.48 0.60 0.66 1.31 1.39 0.39 0.09 0.07
Operating CF/Net income
0.16 (0.07) 1.22 0.27 1.22 (2.17) 1.55 0.71 0.33 0.57
Capex/Depreciation
(1.45) (0.60) (0.37) (0.57) 0.85 (3.73) (0.68) (0.31) (0.08) 0.01
Interest Coverage
(17.81) (17.27) (9.78) (24.35) (7.05) 8.54 30.88 (16.76) (11.53) (2.60)
ROE
(38.78%) 214.71% (7.20%) (22.69%) (19.51%) 18.13% 30.20% (29.70%) (188.11%) (271.49%)
ROA
(20.76%) 174.72% (6.40%) (19.06%) (9.73%) 10.39% 20.87% (18.69%) (68.80%) (23.96%)
ROIC
(33.82%) (25.17%) (12.36%) (20.51%) (10.47%) 11.82% 30.16% (23.65%) (100.08%) (122.44%)
Return on Tangible Assets
(48.10%) 138.31% (10.54%) (27.74%) (16.13%) 12.12% 35.47% (45.29%) (888.81%) 30.78%
Average Days of Receivables
500.73 164.43 216.84 252.13 79.34 174.13 110.27 373.66 1,081.41 129.03
Research and Development Expense of Revenue
8.51% 4.37% 3.03% 3.36% 4.36% 0.66% 0.53% 4.01% 8.77% 2.46%
Selling, General and Administrative Expense of Revenue
105.40% 55.81% 45.84% 55.91% 51.66% 28.46% 28.04% 95.59% 559.60% 444.74%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.07 0.19 0.16 0.19 0.24 0.19
Share Based Compensation of Revenue
0.02% 0.79% 4.83% 7.53% 10.05% 4.03% 3.25% 10.11% 53.74% 43.57%
Graham Net Nets
0.08 0.76 0.39 0.39 (0.05) 0.28 0.24 0.06 (1.66) (13.93)
Graham Number
0.00 110.31 0.00 0.00 0.00 58.97 104.13 0.00 0.00 0.00
Earnings Yield
(8.37%) 118.00% (4.71%) (14.23%) (2.05%) 5.58% 12.54% (21.12%) (313.56%) (386.58%)
Free Cash Flow Yield
(3.24%) (8.74%) (120.04%) (4.69%) (2.07%) (24.74%) 16.54% (17.44%) (119.84%) (215.29%)
Revenue per Share
2.46 6.34 11.52 8.54 12.52 52.10 77.40 20.33 3.39 0.51
Operating CF per Share
(0.28) (1.82) (1.86) (0.73) (2.24) (8.98) 18.02 (6.91) (8.77) (0.98)
Capex per Share
(0.38) (0.13) (0.12) (0.20) 0.34 (8.76) (2.19) (1.18) (0.34) 0.01
Free Cash Flow per Share
(0.66) (1.96) (1.98) (0.92) (1.90) (17.74) 15.83 (8.09) (9.11) (0.97)
Cash per Share
0.26 14.09 7.23 1.18 7.29 11.54 11.00 2.75 0.34 0.01
Shareholders Equity per Share
3.49 20.46 14.48 9.71 9.10 38.64 40.16 28.70 3.68 0.41
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
3.49 20.46 14.48 9.71 9.10 38.64 40.16 28.70 3.68 0.41
Free Cash Flow
(1.12) (3.05) (2.26) (1.07) (2.20) (26.92) 25.08 (13.93) (18.21) (8.22)
Working Capital
2.79 26.61 14.01 9.01 9.59 45.79 44.76 26.73 (1.50) (49.93)
Capital Expenditures
(0.65) (0.21) (0.14) (0.23) 0.39 (13.30) (3.47) (2.04) (0.68) 0.12
Net Current Asset Value
2.79 26.61 14.01 8.90 (4.96) 30.65 36.82 5.04 (25.21) (53.21)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 10.40 5.80 0.00 0.00 0.00
Capex to Sales
0.15 0.02 0.01 0.02 (0.03) 0.17 0.03 0.06 0.10 (0.03)
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 11.10 6.43 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.14 0.13 0.15 0.17 0.13 0.60 0.70 0.64 1.08 5.07
Cash ROIC
(14.23%) (5.66%) (9.13%) (8.49%) (7.50%) (30.99%) 29.94% (21.25%) (71.48%) (87.56%)
Accounts Receivable Turnover
0.86 1.93 2.14 1.35 2.91 3.87 3.28 0.96 0.24 0.40
Accounts Payable Turnover
2.04 5.83 16.71 16.71 4.71 6.86 8.04 2.67 0.62 0.11
Inventory Turnover
0.91 3.71 4.86 4.32 4.41 9.70 12.13 6.20 4.03 4.88
Average Days of Payables
245.23 25.90 19.11 21.72 138.92 69.21 41.45 162.40 723.51 4,999.92
Days of Inventory on Hand
311.20 70.57 83.23 73.34 111.95 45.31 27.91 43.04 60.29 8.63
Average Receivables
4.89 5.11 6.12 7.31 4.99 20.43 37.38 36.43 27.94 10.80
Average Payables
1.57 1.36 0.50 0.43 2.10 5.40 6.47 7.27 11.18 27.14
Average Inventory
3.53 2.13 1.72 1.68 2.25 3.82 4.29 3.13 1.72 0.61
Average Assets
13.82 23.23 27.20 16.51 21.84 60.35 88.47 89.79 77.56 61.54
Average Common Equity
7.40 18.90 24.18 13.87 10.89 34.59 61.13 56.51 28.37 5.43

Fold the line items

Columns are period end dates